Pharvaris BV at Life Sciences Partners BioCapital Europe Conference (Virtual) Transcript
Joining us now is Berndt Modig, CEO of Pharvaris. Mr. Modig is a co-founder of the company and has served as Chief Executive Officer since inception. He is also a Director, and prior to co-founding the company, Mr. Modig served as Chief Financial Officer of Prosensa Holding, a biopharmaceutical company focused on novel RNA modulating treatment for rare diseases like Duchenne muscular dystrophy from March 2010 through its IPO on NASDAQ in 2013, and until its acquisition by BioMarin Pharmaceuticals in January 2015.
Pharvaris is a clinical-stage company focused on bringing oral bradykinin B2 receptor antagonists to patients by targeting this clinically-proven therapeutic target with novel small molecules. The Pharvaris team is advancing new alternatives to injected therapies for all subtypes of HAE and other bradykinin mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE.
And I'm looking forward to Berndt's presentation. The company has also quite recently IPO-ed on NASDAQ,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |